Pitolisant
Active ingredient: Pitolisant Hydrochloride
In short: Pitolisant Tablets are indicated for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy. Pediatric use information is approved for Harmony Biosciences Management Inc.'s WAKIX (pitolisant) tablets.
What is Pitolisant used for?
Pitolisant Tablets are indicated for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy.
Pediatric use information is approved for Harmony Biosciences Management Inc.'s WAKIX (pitolisant) tablets. However, due to Harmony Biosciences Management Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.
Pitolisant dosage
Consider genotyping patients for CYP2D6 metabolizer status to determine the maximum recommended dosage .
The recommended dosage range for pitolisant tablets for the treatment of EDS in adult patients is 17.8 mg to 35.6 mg administered orally once daily in the morning upon wakening.
Titrate dosage as follows:
Week 1: Initiate with a dosage of 8.9 mg (two 4.45 mg tablets) once daily
Week 2: Increase dosage to 17.8 mg (one 17.8 mg tablet) once daily
Week 3:May increase to the maximum recommended dosage of 35.6 mg (two 17.8 mg tablets) once daily
Dose may be adjusted based on tolerability. If a dose is missed, patients should take the next dose the following day in the morning upon wakening. It may take up to 8 weeks for some patients to achieve a clinical response.
Pediatric use information is approved for Harmony Biosciences Management Inc.'s WAKIX (pitolisant) tablets. However, due to Harmony Biosciences Management Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.
Adult Patients with Moderate (Child-Pugh Class B) Hepatic Impairment
Initiate pitolisant tablets at 8.9 mg once daily and increase after 14 days to a maximum recommended dosage of 17.8 mg once daily [see Warnings and Precautions (5.1), Use in
Specific Populations (8.6), Clinical Pharmacology (12.3)].
Pitolisant tablets are contraindicated in patients with severe hepatic impairment. Pitolisant tablets have not been studied in patients with severe hepatic impairment [see Contraindications (4), Warnings and Precautions (5.1), Use in Specific Populations (8.6), Clinical Pharmacology (12.3
)].
Pediatric use information is approved for Harmony Biosciences Management Inc.'s WAKIX (pitolisant) tablets. However, due to Harmony Biosciences Management Inc.'s marketing exclusivity rights, this drug product is not labeled with that information
Adult Patients with eGFR <60 mL/minute/1.73 m2
Initiate pitolisant tablets at 8.9 mg once daily and increase after 7 days to a maximum recommended dosage of 17.8 mg once daily [see Warnings and Precautions (5.1), Use in
Specific Populations (8.7), Clinical Pharmacology (12.3)].
Pitolisant Tablets is not recommended in patients with eGFR less than 15 mL/minute/1.73 m2 [see Warnings and Precautions (5.1), Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
Pediatric use information is approved for Harmony Biosciences Management Inc.'s WAKIX (pitolisant) tablets. However, due to Harmony Biosciences Management Inc.'s marketing exclusivity rights, this drug product is not labeled with that information
Coadministration with Strong CYP2D6 Inhibitors
Adult patients: Initiate Pitolisant Tablets at 8.9 mg once daily and increase after 7 days to a maximum recommended dosage of 17.8 mg once daily . …
How to take Pitolisant — instructions & advice from the label
Prolongation of the QT Interval
Inform patients to consult their physician immediately if they feel faint, lose consciousness, or have heart palpitations . Advise patients to inform their healthcare provider that they are taking pitolisant tablets before any new drug is taken.
Contraception
Advise patients that use of pitolisant tablets may reduce the efficacy of hormonal contraceptives. Advise patients using a hormonal contraceptive to use an alternative non-hormonal contraceptive method of contraception during treatment and for at least 21 days after discontinuing treatment .
Concomitant Medication
Advise patients to inform their healthcare provider if they are taking, or plan to take, any prescription or over-the-counter drugs, because of the potential for interactions between pitolisant tablets and other drugs .
LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc.
The brands listed are trademarks of their respective owners and are not trademarks of Lupin Limited. The makers of these brands are not affiliated with and do not endorse Lupin Limited or its products.
Manufactured for:
Lupin Pharmaceuticals, Inc. …
Warnings & precautions
Do not take this medicine if: Pitolisant tablets are contraindicated in patients with:
known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported in patients treated with pitolisant tablets .
severe hepatic impairment. Pitolisant tablets are extensively metabolized by the liver and there is a significant increase in pitolisant tablets exposure in patients with moderate hepatic impairment .
Pitolisant tablets prolong the QT interval. The use of pitolisant tablets should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval . Pitolisant tablets should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval . The risk of QT prolongation may be greater in patients with higher concentrations of pitolisant (e.g., patients with hepatic or renal impairment). Monitor patients with hepatic or renal impairment for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment . Pitolisant tablets are contraindicated in patients with severe hepatic impairment . Pitolisant tablets are not recommended in patients with end-stage renal disease (ESRD) [see Dosage and Administration (2.5), Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
Pitolisant side effects
The following adverse reactions are discussed in more detail in other sections of the labeling:
QT Interval Prolongation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult Patients with Narcolepsy
In clinical trials for narcolepsy, 172 adult patients were treated with pitolisant tablets in placebo-controlled trials for up to 8 weeks and in open-label extension trials for up to 5 years. In trials in which pitolisant tablets was directly compared to placebo, 6 of the 152 patients (3.9 %) who received pitolisant tablets and 4 of the 114 patients (3.5 %) who received placebo discontinued because of an adverse reaction.
Most Common Adverse Reactions
In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (occurring in ≥5 % of patients and at least twice the rate of placebo) with the use of pitolisant tablets were insomnia (6 %), nausea (6 %), and anxiety (5 %).
Table 1 presents the adverse reactions that occurred at a rate of ≥2 % in patients treated with pitolisant tablets and more frequently than in patients treated with placebo in the placebo-controlled clinical trials in narcolepsy. …
Drug interactions
Effect of Other Drugs on Pitolisant Tablets
Strong CYP2D6 Inhibitors
Clinical Implication: | Concomitant administration of pitolisant tablets with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold.
Prevention or Management: | Reduce the dose of pitolisant tablets by half .
Strong CYP3A4 Inducers
Clinical Implication: | Concomitant use of pitolisant tablets with strong CYP3A4 inducers decreases exposure of pitolisant by 50 %.
Prevention or Management: | Assess for loss of efficacy after initiation of a strong CYP3A4 inducer. For patients stable on pitolisant tablets 8.9 mg or 17.8 mg once daily, increase the dose of pitolisant tablets to reach double the original daily dose (i.e., 17.8 mg or 35.6 mg, respectively) over 7 days. If concomitant dosing of a strong CYP3A4 inducer is discontinued, decrease pitolisant tablets dosage by half .
Histamine-1 (H1) Receptor Antagonists
Clinical Implication: | Pitolisant tablets increase the levels of histamine in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of pitolisant tablets.
Prevention or Management: | Avoid centrally acting H1 receptor antagonists. …
About this medicine
Pitolisant tablets contain pitolisant hydrochloride. Pitolisant is an antagonist/inverse agonist of the histamine-3 (H3) receptor. Pitolisant hydrochloride is a white to white powder with a molecular formula of C17H27Cl2NO and a molecular weight of 332.3. Pitolisant hydrochloride is freely soluble in methanol and water. The chemical name of pitolisant hydrochloride is 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride and its structural formula is:
The molecular formula of the pitolisant free base is C17H26ClNO and its molecular weight is 295.85.
Pitolisant tablets are for oral administration and each film-coated tablet contains 5 mg or 20 mg of pitolisant hydrochloride (equivalent to 4.45 mg or 17.8 mg of pitolisant free base, respectively) and the following inactive ingredients: crospovidone, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, silicon dioxide, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6fb94d86-5154-4b69-8470-d1145d426312. Read the full official label on DailyMed.
Related medicines
Tirzepatide Buspirone Venlafaxine Zolpidem Citalopram Lorazepam Temazepam Melatonin